MedTrace Logo

Fuzheng Huayu Tablets Against Posthepatitic Cirrhosis

NCT00543426 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2013-03-07

No results posted yet for this study

Summary

The primary purpose of the trial is adopted Fuzheng Huayu tablets against posthepatitic cirrhosis, and to build a standard evaluation system for efficacy of traditional Chinese medicine (TCM).

The second purpose is according to the international clinical guideline and the specialty of TCM to build a standard clinical trial regulation for traditional Chinese medicine.

Conditions

  • Posthepatitic Cirrhosis

Interventions

DRUG

Fuzheng Huayu Tablets

Tablet,three times a day,four tablets one time

DRUG

sham Fuzheng Huayu Tablets (placebo)

Tablet, three times a day, four tablets one time

Sponsors & Collaborators

  • Shanghai University of Traditional Chinese Medicine

    lead OTHER

Principal Investigators

  • Zengzeng Cai, Ph.D · Shanghai Univercity of TCM

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2009-05-31
Completion
2009-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00543426 on ClinicalTrials.gov